Related Experiment Video

Updated: Oct 1, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Synagis: an anti-RSV monoclonal antibody

L C Driver1, M D Oertel

  • 1University of North Carolina Hospitals, Chapel Hill, NC, USA.

Pediatric Nursing
|May 25, 2002
PubMed

Insights

Palivizumab significantly reduced respiratory syncytial virus (RSV) hospitalizations by 55% in high-risk infants. This monoclonal antibody also decreased illness severity, though its cost-effectiveness requires further evaluation.

Area of Science:

  • Pediatric Infectious Diseases
  • Immunology
  • Respiratory Medicine

Background:

  • Respiratory Syncytial Virus (RSV) poses a significant threat to high-risk pediatric populations.
  • Serious lower respiratory tract disease caused by RSV necessitates preventative strategies.

Purpose of the Study:

  • To evaluate the efficacy of palivizumab (Synagis) in preventing RSV-related hospitalizations in high-risk infants.
  • To assess the impact of palivizumab on the severity of RSV illness in pediatric patients.

Main Methods:

  • A large, single clinical trial (IMpact) assessed palivizumab's effectiveness.
  • Study population included infants born prematurely and those with Bronchopulmonary Dysplasia (BPD).

Main Results:

  • Palivizumab reduced RSV hospital admissions by 55% in eligible children.
  • A decrease in total hospitalization days and intensive care unit admissions was observed.
  • The cost of palivizumab prophylaxis ranges from $3,500-$10,700 per infant per season.

Conclusions:

  • Palivizumab demonstrates significant efficacy in reducing RSV hospitalizations and illness severity in high-risk infants.
  • The high cost of palivizumab necessitates formal cost-effectiveness evaluations.
  • American Academy of Pediatrics (AAP) guidelines assist in identifying optimal candidates for RSV prophylaxis.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rabies01:28

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...